Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

191.21 -1.74 (-0.90%)
Streaming Delayed Price Updated: 11:00 AM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
59 60 Next >
News headline image
What Does Biogen's Debt Look Like? ↗
Shares of Biogen Inc. (NASDAQ:BIIB) moved lower by 7.52% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its... 
Via Benzinga
News headline image
Peering Into Biogen's Recent Short Interest ↗
Biogen's (NASDAQ:BIIB) short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that... 
Via Benzinga
News headline image
Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval ↗
The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys. 
Via Investor's Business Daily
News headline image
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
From Biogen Inc.
Via GlobeNewswire
News headline image
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit ↗
The FDA is set to review the company's neurological drug by Tuesday. 
Via Investor's Business Daily
News headline image
Biogen (BIIB) Q4 2022 Earnings Call Transcript ↗
BIIB earnings call for the period ending December 31, 2022. 
Via The Motley Fool
News headline image
Why Biogen Stock Is Falling Today ↗
 
Via Benzinga
News headline image
Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales ↗
The company expects "modest" Leqembi sales, but there's a caveat. 
Via Investor's Business Daily
News headline image
Why Reata Pharmaceuticals Shares Are Falling Monday? ↗
According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. 
Via Benzinga
News headline image
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca ↗
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
News headline image
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
News headline image
Analyst Initiates Coverage of GE Healthcare, Says' Path To Greatness Well-Paved' ↗
 
Via Benzinga
News headline image
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up ↗
Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05. 
Via Talk Markets
News headline image
2 Top Biotech Stocks Defying the Bear Market ↗
These stocks soared in the double digits last year. 
Via The Motley Fool
News headline image
Is Biogen Stock a Buy Now? ↗
Its new drug might succeed where the company faltered in 2021. 
Via The Motley Fool
News headline image
Cisco, Analog Devices And 3 Stocks To Watch Heading Into Wednesday ↗
With US futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
US Stocks Settle Mixed; Investor Optimism Improves ↗
The CNN Money Fear and Greed index showed an improvement in the overall sentiment among US investors. 
Via Benzinga
News headline image
Investors Are Awaiting The Name Of The New BoJ Governor ↗
This week, the Japanese government will officially elect a new Governor of the Bank of Japan to replace Haruhiko Kuroda, whose decade at the Central Bank will end in April. 
Via Talk Markets
News headline image
Q4 Reporting Season Pushes Past Halfway Mark: Coca-Cola, Cisco Systems, Palantir, Roku Lead Earnings This Week ↗
The stock market pulled back in the week ended Feb. 10, dragged by some disappointing earnings and revised December inflation data. 
Via Benzinga
News headline image
Why Anavex Life Sciences Stock Bolted Higher in January ↗
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results. 
Via The Motley Fool
News headline image
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive' ↗
 
Via Benzinga
News headline image
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
News headline image
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
News headline image
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023 ↗
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy. 
Via InvestorPlace
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
7 CRISPR Stocks With the Best Long-Term Potential ↗
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
News headline image
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
News headline image
Lecanemab Receives Priority Review Status in Japan
From Biogen Inc.
Via GlobeNewswire
News headline image
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.